A monocentric observational study of darbepoetin alfa in anemic hepatitis-C-virus transplant patients treated with ribavirin

Experimental and Clinical Transplantation

Volumn 6, Issue 4, 2008, Pages 271-275

  Kamar, Nassim ^a,b   Guitard, Joëlle ^a   Ribes, David ^a   Esposito, Laure ^a   Rostaing, Lionel ^a,c  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b CHU RANGUEIL   (France)

^c CHU PURPAN   (France)

Author keywords

Hepatitis C; Observational study; Organ transplant; Ribavirin; Transplant patients

Indexed keywords

ANTIANEMIC AGENT; ANTIVIRUS AGENT; CREATININE; DRUG DERIVATIVE; ERYTHROPOIETIN; IMMUNOSUPPRESSIVE AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RIBAVIRIN; VIRUS RNA;

ANEMIA; ARTICLE; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; FEMALE; GENETICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; PATHOPHYSIOLOGY; PILOT STUDY; POSTOPERATIVE CARE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANEMIA; ANTIVIRAL AGENTS; CHRONIC DISEASE; CREATININE; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; PILOT PROJECTS; POSTOPERATIVE CARE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 65249190067     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Rigatto C. Anemia, renal transplantation, and the anemia paradox. Semin Nephrol. 2006;26(4):307-312.
2. Gervais A, Boyer N, Marcellin P. Tolerability of treatments for viral hepatitis. Drug Saf. 2001;24(5):375-384.
3. Bruchfeld A, Lindahl K, Ståhle L, Söderberg M, Schvarcz R. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant. 2003;18(8):1573-1580.
4. Locatelli F, Aljama P, Bárány P, et al. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(suppl 2):21-247
5. Sherman M, Cohen L, Cooper MA, et al. Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin. Can J Gastroenterol. 2006;20(7):479-485.
6. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant. 2001;16(suppl 3):3-13.
7. Robinson DM, Easthope SE. Darbepoetin alfa: its use in anemia associated with chronic kidney disease. BioDrugs. 2005;19(5):327-343.
8. Afzali B, Al-Khoury S, Shah N, Mikhail A, Covic A, Goldsmith D. Anemia after renal transplantation. Am J Kidney Dis. 2006;48(4):519-536.
9. NKF (National Kidney Foundation). K/DOQI IV Clinical practice recommendations for anemia in chronic kidney disease in transplant recipients. Am J Kidney Dis. 2006; 47 (5 Suppl 3): S109.
10. Oze T, Hiramatsu N, Kurashige N, et al. Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C. J Gastroenterol. 2006;41(9):862-872.
11. Russmann S, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem. 2006;13(27):3351-3357.
12. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in hepatitis C virus-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. 2004;126(5):1302-1311.
13. Collantes RS, Younossi ZM. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. J Clin Gastroenterol. 2005;39(suppl 1):S9-S13.
14. Dieterich DT, Wasserman R, Bräu N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol. 2003;98(11):2491-2499.
15. Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med. 2004;7(1 Suppl 3):S17-S21.
16. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat. 2006;13(5):316-321.